WO 2000071538 A2		WO 2000-IB493	20000420
AU 2000036673 A		AU 2000-36673	20000420
US 6239147	B1 Provisional	US 1999-135399	19990521
		US 2000-572213	20000517

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000036673 A	Based on	WO 200071538

PRIORITY APPLN. INFO: US 1999-135399 19990521; US 2000-572213 20000517

L2 ANSWER 5 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-656203 [63] WPIDS
DOC. NO. CPI: C2000-198607
TITLE: Use of CYP2D6 inhibitors for improving pharmacokinetic profile of drugs, cleared by CYP2D6 mediated oxidative biotransformation.
DERWENT CLASS: B03 B05
INVENTOR(S): **OBACH, R S**
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
COUNTRY COUNT: 90
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000059486 A2		20001012	(200063)*	EN	17
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW				
AU 2000031850 A		20001023	(200107)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000059486 A2		WO 2000-IB304	20000320
AU 2000031850 A		AU 2000-31850	20000320

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000031850 A	Based on	WO 200059486

PRIORITY APPLN. INFO: US 1999-128136 19990407

```
=> s e4-e6
L2            5 ("OBACH R S"/IN OR "OBACH R SCOTT"/IN OR "OBACH RONALD
SCOTT"/IN
                )

=> d ibib 1-5

L2    ANSWER 1 OF 5       PCTFULL  COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:         2000071538 PCTFULL  EW 200048  ED 20001215
TITLE (ENGLISH):          1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-
                          AMINOMETHYLCHROMAN DERIVATIVES
TITLE (FRENCH):           DERIVES 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYL-
                          AMINOMETHYLCHROMANE
INVENTOR(S):              OBACH, Ronald, Scott; SCULLY, Douglas, Alan
PATENT ASSIGNEE(S):       PFIZER PRODUCTS INC.
LANGUAGE OF PUBL.:        English
LANGUAGE OF FILING:       English
DOCUMENT TYPE:            Patent
PATENT INFORMATION:
                          NUMBER              KIND     DATE
                          ---------------------------------
                          WO 2000071538         A2 20001130
DESIGNATED STATES:        AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
                          DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
                          KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
                          NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
                          UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
                          AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
                          GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
                          ML MR NE SN TD TG
APPLICATION INFO.:        WO 2000-IB493           20000420
PRIORITY (ORIGINAL):      US 1999-60/135399       19990521

L2    ANSWER 2 OF 5       PCTFULL  COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:         2000059486 PCTFULL  EW 200041  ED 20001024
TITLE (ENGLISH):          USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES
TITLE (FRENCH):           UTILISATION D'INHIBITEURS CYP2D6 DANS DES
                          POLYTHERAPIES
INVENTOR(S):              OBACH, Ronald, Scott
PATENT ASSIGNEE(S):       PFIZER PRODUCTS INC.
LANGUAGE OF PUBL.:        English
LANGUAGE OF FILING:       English
DOCUMENT TYPE:            Patent
PATENT INFORMATION:
                          NUMBER              KIND     DATE
                          ---------------------------------
                          WO 2000059486         A2 20001012
DESIGNATED STATES:        AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
                          DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
                          KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
                          NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
                          UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
                          AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
                          GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
                          ML MR NE SN TD TG
APPLICATION INFO.:        WO 2000-IB304           20000320
PRIORITY (ORIGINAL):      US 1999-60/128136       19990407
```

L2 ANSWER 3 OF 5 USPATFULL

ACCESSION NUMBER: 2001:79172 USPATFULL

TITLE: 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives

INVENTOR(S): **Obach, R. Scott**, Gales Ferry, CT, United States
Scully, Douglas Alan, Noank, CT, United States

PATENT ASSIGNEE(S): Pfizer INC, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6239147	B1	20010529
APPLICATION INFO.:	US 2000-572213		20000517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-135399	19990521 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1229
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2001-049878 [06] WPIDS

DOC. NO. CPI: C2001-013713

TITLE: New 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives are substance P antagonists used for treating e.g. CNS and gastrointestinal disorders.

DERWENT CLASS: B02

INVENTOR(S): **OBACH, R S**; SCULLY, D A

PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC; (PFIZ) PFIZER INC

COUNTRY COUNT: 90

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000071538	A2	20001130	(200106)*	EN	29

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000036673	A	20001212	(200115)
US 6239147	B1	20010529	(200132)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN **145742-28-5** REGISTRY
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S-cis)-
OTHER NAMES:
CN CP 122721
FS STEREOSEARCH
MF C20 H23 F3 N2 O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, DRUGUPDATES, EMBASE, IPA, PROMT, TOXLIT, USPATFULL

Absolute stereochemistry.



35 REFERENCES IN FILE CA (1967 TO DATE)
35 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.05	169.31

FILE 'CAPLUS' ENTERED AT 15:20:50 ON 06 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 6 Aug 2001 VOL 135 ISS 7
FILE LAST UPDATED: 5 Aug 2001 (20010805/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for

more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

=> s l12
L13 35 L12

=> d ti 1-35

L13 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists for the treatment of symptoms of irritable bowel
syndrome

L13 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Nitric oxide synthase (NOS) inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm

L13 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures

L13 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Use of CYP2D6 inhibitors in combination therapies

L13 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Combination of macrolide antibiotics and substance P antagonists as antiemetic agents, and their pharmaceutical compositions

L13 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Probable involvement of the 5-hydroxytryptamine4 receptor in methotrexate-induced delayed emesis in dogs

L13 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew)

L13 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Use of NK-1 receptor antagonists for manufacture of a medicament for treating emesis

L13 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist

```
=> s e1-e81
           730 10262-69-8/BI
          3947 10540-29-1/BI
           153 106133-20-4/BI
           572 106266-06-2/BI
           474 1131-64-2/BI
           328 113775-47-6/BI
           598 114-86-3/BI
            56 115956-12-2/BI
            60 124937-51-5/BI
           415 125-28-0/BI
           431 125-29-1/BI
          1106 125-71-3/BI
             9 131831-03-3/BI
            27 133454-47-4/BI
            31 134234-12-1/BI
           899 13655-52-2/BI
           153 136817-59-9/BI
            35 145742-28-5/BI
           580 155213-67-5/BI
          1248 2062-78-4/BI
            68 2165-19-7/BI
          1277 24219-97-4/BI
           115 25905-77-5/BI
           993 26839-75-8/BI
           185 26844-12-2/BI
           410 27203-92-5/BI
           349 27848-84-6/BI
           206 29216-28-2/BI
           594 298-57-7/BI
          1768 303-49-1/BI
           612 31828-71-4/BI
           534 3239-44-9/BI
            44 35080-11-6/BI
           203 37640-71-4/BI
           579 42542-10-9/BI
           570 483-04-5/BI
          3943 50-47-5/BI
          3599 50-48-6/BI
          5637 50-49-7/BI
          1718 50-52-2/BI
          1436 51-06-9/BI
           585 51384-51-1/BI
          7538 52-86-8/BI
           881 52468-60-7/BI
          8969 525-66-6/BI
          3083 537-46-2/BI
           127 53772-83-1/BI
          3262 54-05-7/BI
           488 54063-53-5/BI
           376 54143-55-4/BI
           606 54739-18-3/BI
          1900 54910-89-3/BI
          2855 56-54-2/BI
           196 5633-20-5/BI
          1199 58-39-9/BI
          2102 60-87-7/BI
```

e18

884	61869-08-7/BI
62	62498-67-3/BI
80	63638-91-5/BI
95	64-13-1/BI
140	6621-47-2/BI
107	66778-36-7/BI
447	68-88-2/BI
183	69756-53-2/BI
339	71320-77-9/BI
1659	72-69-5/BI
433	76-42-6/BI
3196	76-57-3/BI
746	76-58-4/BI
59	77518-07-1/BI
584	79617-96-2/BI
98	80012-43-7/BI
253	83-74-9/BI
50	83015-26-3/BI
392	89565-68-4/BI
1058	90-39-1/BI
30910	9035-51-2/BI
448	91-81-6/BI
155	93-30-1/BI
318	93413-69-5/BI
760	99614-02-5/BI

```
=> d his

     (FILE 'HOME' ENTERED AT 18:02:56 ON 06 AUG 2001)

     FILE 'USPATFULL' ENTERED AT 18:03:50 ON 06 AUG 2001
L1            72 S CYP2D6
L2             4 S L1(L)(HEPATIC(5A)METABOLISM)
L3            66 S L1(L)METABOLISM
L4            10 S L3 NOT PY>=1999
```

L4 ANSWER 9 OF 10 USPATFULL

ACCESSION NUMBER:	95:47624 USPATFULL
TITLE:	Methods and compositions for the expression of biologically active fusion proteins comprising a eukaryotic cytochrome P450 fused to a reductase in bacteria
INVENTOR(S):	Fisher, Charles W., Dallas, TX, United States Barnes, Henry J., Chula Vista, CA, United States Estabrook, Ronald W., Dallas, TX, United States
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5420027		19950530
APPLICATION INFO.:	US 1992-908317		19920702 (7)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-640473, filed on 10 Jan 1991, now patented, Pat. No. US 5240831
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Wax, Robert A.
ASSISTANT EXAMINER:	Moore, William W.
LEGAL REPRESENTATIVE:	Arnold, White & Durkee
NUMBER OF CLAIMS:	49
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT:	2930

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL

ACCESSION NUMBER:	93:71980 USPATFULL
TITLE:	Methods and compositions for the expression of biologically active eukaryotic cytochrome P450S in bacteria
INVENTOR(S):	Barnes, Henry J., Dallas, TX, United States
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5240831		19930831
APPLICATION INFO.:	US 1991-640473		19910110 (7)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Wax, Robert A.
ASSISTANT EXAMINER:	Moore, William W.
LEGAL REPRESENTATIVE:	Arnold, White Durkee
NUMBER OF CLAIMS:	49
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT:	1565

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:430066 CAPLUS
DOCUMENT NUMBER: 129:95404
TITLE: Preparation of [(Fluoroalkoxy)benzylamino]piperidine derivatives as substance P receptor antagonists
INVENTOR(S): Lowe, John Adams, III; Rosen, Terry Jay
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 19 pp. Cont.-in-part of U. S. 717,943, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5773450	A	19980630	US 1993-167881	19931214
WO 9300331	A1	19930107	WO 1992-US3571	19920505
W: AU, BR, CA, CS, DE, FI, HU, JP, KR, NO, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
HU 70499	A2	19951030	HU 1995-836	19920505
US 5744480	A	19980428	US 1995-443418	19950522

PRIORITY APPLN. INFO.:

US 1991-717943	B2	19910620
WO 1992-US3571	W	19920505
US 1993-167881	A3	19931214
HU 1993-3668	A	19931220

have compound.

L18 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:293247 CAPLUS

DOCUMENT NUMBER: 125:26019

TITLE: Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor

AUTHOR(S): Mclean, S.; Ganong, A.; Seymour, P. A.; Bryce, D. K.; Crawford, R. T.; Morrone, J.; Reynolds, L. S.; Schmidt, A. W.; Zorn, S.; et al.

CORPORATE SOURCE: Dep. Neurosci., Pfizer Inc., Groton, CT, 06340, USA

SOURCE: J. Pharmacol. Exp. Ther. (1996), 277(2), 900-908
CODEN: JPETAB; ISSN: 0022-3565

DOCUMENT TYPE: Journal

LANGUAGE: English

L18 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:595919 CAPLUS
DOCUMENT NUMBER: 121:195919
TITLE: Pharmaceutical agents for treatment of urinary incontinence
INVENTOR(S): Desai, Manoj C.; Lowe, Iii John A.; Rosen, Terry J.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 610021	A1	19940810	EP 1994-300575	19940126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5340826	A	19940823	US 1993-13277	19930204
US 5519033	A	19960521	US 1994-251493	19940531
PRIORITY APPLN. INFO.:			US 1993-13277	19930204

```
> d his

     (FILE 'HOME' ENTERED AT 16:07:18 ON 06 AUG 2001)

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:12:22 ON 06 AUG 2001

     FILE 'EUROPATFULL, PCTFULL, USPATFULL, WPIDS' ENTERED AT 16:12:36 ON 06
     AUG 2001
L1           355 S CYP2D6
L2       1433957 S CLEAR?
L3             4 S CLEAR?(7A)(OXID?(3A)BIOTRANSFORM?)
L4            71 S (OXID?(3A)BIOTRANSFORM?)
L5             0 S L1(L)(NEROKININ?)
L6           159 S L1(L)CLEAR?
L7            46 S L1(L)(CLEARANCE OR HEPATIC(3A)METABOLI?)
L8            42 S L7(L)OXID?
L9             8 S L8 NOT PY>=1999
L10           40 S L7(L)INHIBIT?
L11            7 S L10 NOT PY>=1999
```

L13 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity

L13 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Chronic non-peptide neurokinin receptor antagonist treatment alters striatal tachykinin peptide and receptor gene expression in the rat

L13 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Preparation of [(Fluoroalkoxy)benzylamino]piperidine derivatives as substance P receptor antagonists

L13 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist

L13 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Stereoselective preparation of substituted piperidines

L13 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Determination of the substance P receptor antagonist CP-122,721 in plasma by narrow-bore high-performance liquid chromatography-ionspray tandem mass spectrometry

L13 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin

L13 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists for the treatment of cancer

L13 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Antiemetic composition containing an NK-1 receptor antagonist

L13 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy

L13 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists for the treatment of neuronal injury and stroke

L13 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists for the treatment of neuronal injury and stroke

L13 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists and 5-HT3 receptor antagonists for the treatment of emesis

L13 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI NK-1 receptor antagonists for the treatment of eye disorders

L13 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2001 ACS
TI Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets

```
L13  ANSWER 25 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin
     NK1 receptor

L13  ANSWER 26 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Pharmaceutical agents for the inhibition of angiogenesis

L13  ANSWER 27 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Pharmaceuticals for treatment or prevention of sunburn.

L13  ANSWER 28 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Substance P antagonists for treatment of disorders caused by Helicobacter
     pylori or other spiral urease-positive gram-negative bacteria

L13  ANSWER 29 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Substance P antagonists for the treatment of emesis

L13  ANSWER 30 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Use of tachykinin antagonists in the treatment of emesis

L13  ANSWER 31 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Pharmaceutical agents for treatment of urinary incontinence

L13  ANSWER 32 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   2-Step formylation process for preparation of (methoxy)benzaldehydes

L13  ANSWER 33 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Process for the preparation of substituted cis-3-aminopiperidine
substance
     P receptor antagonists

L13  ANSWER 34 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Preparation of 3-[(fluoroalkoxy)benzylamino]piperidines and analogs as
     substance P antagonists

L13  ANSWER 35 OF 35  CAPLUS  COPYRIGHT 2001 ACS
TI   Stereoselective process for the preparation of
N-(arylmethyl)-cis-2-aryl-3-
     piperidinamines  by reductive benzylation or alkylation of
     cis-2-aryl-3-piperidinamine


=> s cytochrome or cyp?
         91962 CYTOCHROME
         12499 CYTOCHROMES
         93824 CYTOCHROME
                 (CYTOCHROME OR CYTOCHROMES)
         29254 CYP?
L14     114428 CYTOCHROME OR CYP?

=> s l13(l)l14
L15          1 L13(L)L14

=> d ibib 1

L15  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:        2000:725447  CAPLUS
```

DOCUMENT NUMBER:	133:301178
TITLE:	Use of CYP2D6 inhibitors in combination therapies
INVENTOR(S):	Obach, Ronald Scott
PATENT ASSIGNEE(S):	Pfizer Products Inc., USA
SOURCE:	PCT Int. Appl., 18 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

L9 ANSWER 6 OF 8 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1995020980 PCTFULL
TITLE (ENGLISH): METHOD FOR INCREASING BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOSITIONS
TITLE (FRENCH): PROCEDE PERMETTANT D'ACCROITRE LA BIODISPONIBILITE DES COMPOSITIONS PHARMACEUTIQUES ADMINISTREES PAR VOIE ORALE
INVENTOR(S): BENET, Leslie; WU, Chi, Yuan
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9520980	A1	19950810

DESIGNATED STATES: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1995-US347 19950111
PRIORITY (ORIGINAL): US 1994-8/190288 19940202

ABEN A method for increasing bioavailability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with a bioenhancer comprising an inhibitor of a cytochrome P450 3A enzyme or an inhibitor of P-glycoprotein-mediated membrane transport, the bioenhancer being present in sufficient amount to provide bioavailability of the compound in the presence of the bioenhancer greater than the bioavailability of the compound in the absence of the bioenhancer.

ABF Procede permettant d'accroitre la biodisponibilite d'un compose pharmaceutique hydrophobe administre par voie orale, qui consiste a administrer conjointement par voie orale le compose pharmaceutique a un mammifere necessitant un traitement par ce compose et un biostimulant contenant un inhibiteur d'enzyme P450 3A ou un inhibiteur de transport membranaire par P-glycoproteine, le biostimulant etant present en quantite suffisante pour conferer une biodisponibilite au compose superieure a la biodisponibilite que presenterait le compose en l'absence de ce biostimulant.

L9 ANSWER 7 OF 8 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1992014817 PCTFULL
TITLE (ENGLISH): IN VIVO ASSAY SYSTEMS FOR METABOLIC ROUTES
TITLE (FRENCH): SYSTEMES DE DOSAGE IN VIVO POUR DES MECANISMES METABOLIQUES
INVENTOR(S): WOLF, Charles, Roland; JOWETT, Trevor; BEGGS, Jean, Duthie
PATENT ASSIGNEE(S): IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED; WOLF, Charles, Roland; JOWETT, Trevor; BEGGS, Jean, Duthie
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

	WO 9214817	A1 19920903
DESIGNATED STATES:	AT BE CH DE DK ES FR GB GR IT JP LU MC NL SE US	
APPLICATION INFO.:	WO 1992-GB274	19920217
PRIORITY (ORIGINAL):	GB 1991-9103314.2	19910216

ABEN A cellular organism useful in an assay for determining the metabolism of a compound, the organism comprising in the genome of its cell or at least one of its cells a coding sequence for expressing a polypeptide having the function of a naturally-occurring protein which is involved in the alteration of the metabolism, mutagenicity or toxicity of a compound under the regulatory control of a suitable promoter, the combination of the coding sequence and the promoter not normally being found in the said cell of the said organism. Preferably, the protein is a P450 cytochrome-dependent enzyme. The organism may be yeast (in which case a mammalian NADPH:cytochrome P450 reductase or a hybrid yeast/mammalian P450 reductase can usefully be encoded as well), a rodent (in which case expression in the skin using a keratin promoter is preferred, optionally with co-expression of a glutathione S-transferase) or a Drosophila fly.

ABF Organisme cellulaire qu'on utilise dans un dosage pour determiner le metabolisme d'un compose, ledit organisme comprenant dans le genome de sa cellule ou d'au moins une de ses cellules une sequence de codage permettant d'exprimer un polypeptide presentant la fonction d'une proteine existant naturellement qui est implique dans la modification du metabolisme, la mutagenicite ou la toxicite d'un compose sous l'effet regulateur d'un promoteur approprie, l'association de la sequence de codage et du promoteur ne se trouvant pas normalement dans ladite cellule dudit organisme. De preference, la proteine est une enzyme a dependance cytochrome P450. L'organisme peut etre une levure (dans ce cas, on peut coder utilement egalement une NADPH: cytochrome reductase P450 ou une reductase P450 hybride levure/mammifere), un rongeur (dans ce cas on prefere l'expression dans la peau a l'aide d'un promoteur de keratine, facultativement associee a la co-expression d'une glutathion S-

transferase) ou une mouche Drosophile.

L9 ANSWER 8 OF 8 USPATFULL

ACCESSION NUMBER:	96:96932 USPATFULL
TITLE:	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
INVENTOR(S):	Benet, Leslie, Belvedere, CA, United States Wu, Chi Y., San Francisco, CA, United States
PATENT ASSIGNEE(S):	Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5567592		19961022	
APPLICATION INFO.:	US 1994-190288		19940202	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Nucker, Christine M.			
ASSISTANT EXAMINER:	Parkin, Jeffrey S.			
LEGAL REPRESENTATIVE:	Cooley Godward Castro Huddleson & Tatum			
NUMBER OF CLAIMS:	7			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)			

LINE COUNT: 1596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A screening method for the identification of bioenhancers that increase the bioavailability of an orally administered pharmaceutical compound through the inhibition of P-glycoprotein transport activity in the gut of a mammal is disclosed. These compounds increase the systemic availability of a pharmaceutical compound when administered prior to, or concurrently with, that compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 8 USPATFULL

SUMM Cytochromes 8 Most biotransformation is performed by enzymes called "mixed function **oxidases**" containing cytochromes, molecules with iron-containing rings, that help reduce oxygen to water. The cytochrome-containing enzymes that transform drugs use radical. . .

SUMM . . . of the cytochromes P450. Genetic polymorphisms have been well characterized for the two cytochromes P450 responsible for debrisoquine/sparteine sparteine metabolism (**CYP2D6**; cytochrome families are defined below) and (S)-mephenytoin 4'-hydroxylation (possibly CYP2C19). The second source of inter-individual differences is that several of. . .

SUMM Kronbach, T. D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. " **Oxidation** of midazolam and triazolam by human liver cytochrome P4501IIA4." Mol Pharmacol 36 (1 1989): 89-96.

SUMM Lalka, D., R. K. Griffith, and C. L. Cronenberger. "The **hepatic** first-pass **metabolism** of problematic drugs." J Clin Pharmacol 33 (7 1993): 657-69.

SUMM . . . Aubert, G. Mourad, and P. Maurel. "Cyclosporine A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A **oxidase**) in primary cultures of human hepatocytes and in liver microsomes." Drug Metab Dipos 18 (5 1990): 595-606.

SUMM . . . Stevens, L. A. Shipley, B. J. Ring, A. E. Rettie, and J. R. Cashman. "In vitro methods for assessing human **hepatic** drug **metabolism**: their use in drug development." Drug Metabolism Reviews 25 (4 1993): 453-484.

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN **145742-28-5** REGISTRY
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Piperidinamine, N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenyl-, (2S-cis)-
OTHER NAMES:
CN CP 122721
FS STEREOSEARCH
MF C20 H23 F3 N2 O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, DRUGUPDATES, EMBASE, IPA, PROMT, TOXLIT, USPATFULL

Absolute stereochemistry.



35 REFERENCES IN FILE CA (1967 TO DATE)
35 REFERENCES IN FILE CAPLUS (1967 TO DATE)

```
=> s e3-e12
          2942 PFIZER/PA
             1 "PFIZER CO INC"/PA
             1 "PFIZER HOPSITAL PRODUCTS GROUP INC"/PA
             1 "PFIZER HOSPITAL PRODUCTS"/PA
             1 "PFIZER HOSPITAL PRODUCTS CORP INC"/PA
             2 "PFIZER HOSPITAL PRODUCTS GROUP"/PA
           110 "PFIZER HOSPITAL PRODUCTS GROUP INC"/PA
             2 "PFIZER HOSPITAL PRODUCTS GROUPS INC"/PA
             1 "PFIZER HOSPITAL PRODUCTS INC"/PA
          2790 "PFIZER INC"/PA
L25       2942 (PFIZER/PA OR "PFIZER CO INC"/PA OR "PFIZER HOPSITAL PRODUCTS
               GROUP INC"/PA OR "PFIZER HOSPITAL PRODUCTS"/PA OR "PFIZER
HOSPIT
               AL PRODUCTS CORP INC"/PA OR "PFIZER HOSPITAL PRODUCTS
GROUP"/PA
               OR "PFIZER HOSPITAL PRODUCTS GROUP INC"/PA OR "PFIZER HOSPITAL
               PRODUCTS GROUPS INC"/PA OR "PFIZER HOSPITAL PRODUCTS INC"/PA
OR
               "PFIZER INC"/PA)

=> s l25 amd CYP2D6
MISSING OPERATOR L25 AMD
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l25 and CYP2D6
           504 CYP2D6
L26          5 L25 AND CYP2D6

=> d ibib 1-5

L26  ANSWER 1 OF 5  USPATFULL
ACCESSION NUMBER:        2003:127683  USPATFULL
TITLE:                   3-azabicyclo[3.1.0]hexane derivatives
INVENTOR(S):             McHardy, Stanton F., Coventry, RI, UNITED STATES
                         Liras, Spiros, Stonington, CT, UNITED STATES
                         Heck, Steven D., Norwich, CT, UNITED STATES
PATENT ASSIGNEE(S):      Pfizer Inc. (U.S. corporation)

                              NUMBER         KIND    DATE
                         -------------------- ------ --------
PATENT INFORMATION:      US 2003087898         A1   20030508
APPLICATION INFO.:       US 2002-278142        A1   20021022  (10)

                                NUMBER         DATE
                         -------------------- --------
PRIORITY INFORMATION:    US 2001-338511P      20011022 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49,
                         NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS:        27
EXEMPLARY CLAIM:         1
LINE COUNT:              2509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26  ANSWER 2 OF 5  USPATFULL
ACCESSION NUMBER:        2003:121001  USPATFULL
```

NO ODP

TITLE: Novel variants of the human **CYP2D6** gene
INVENTOR(S): Milos, Patrice M., Cranston, RI, UNITED STATES
Webb, Suzin M., North Stonington, CT, UNITED STATES
PATENT ASSIGNEE(S): **Pfizer Inc.** (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083485	A1	20030501
APPLICATION INFO.:	US 2002-209737	A1	20020731 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309111P	20010731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 3726
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 3 OF 5 USPATFULL
ACCESSION NUMBER: 2001:223875 USPATFULL
TITLE: Method and device for drug-drug interaction testing sample preparation
INVENTOR(S): Ekins, Sean, Indianapolis, IN, United States
Johnson, Diane Lynn, Waterford, CT, United States
Kelly, Kevin George, Gales Ferry, CT, United States
PATENT ASSIGNEE(S): **Pfizer Inc.** (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001049092	A1	20011206
	US 6489094	B2	20021203
APPLICATION INFO.:	US 2001-858972	A1	20010516 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208213P	20000531 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 919

L26 ANSWER 4 OF 5 USPATFULL
ACCESSION NUMBER: 2001:79172 USPATFULL
TITLE: 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
INVENTOR(S): Obach, R. Scott, Gales Ferry, CT, United States
Scully, Douglas Alan, Noank, CT, United States
PATENT ASSIGNEE(S): **Pfizer INC**, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6239147	B1	20010529
APPLICATION INFO.:	US 2000-572213		20000517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-135399P	19990521 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chang, Ceila
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Waldron, Roy F.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1229
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L26 ANSWER 5 OF 5 USPATFULL
ACCESSION NUMBER: 1999:150947 USPATFULL
TITLE: Method for evaluating drug metabolism and reagent compositions therefor
INVENTOR(S): Shimada, Kaoru, Kariya, Japan
Mizutani, Mayumi, Handa, Japan
Naganeo, Fumiharu, Chitagun, Japan
PATENT ASSIGNEE(S): **Pfizer Inc.**, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5989844		19991123
APPLICATION INFO.:	US 1998-132974		19980812 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-IB988	19970813

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Sheyka, Robert F.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 556